FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Czernik Marcin
(Last) (First) (Middle)
SIMOU MENARDOU 8,
RIA COURT 8, OFFICE 101
(Street)
6015 LARNACA G4
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/17/2014
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
COMMON STOCK 09/17/2014   S   9,569 D $ 40.2623 (1) 2,925,793 I See Footnotes (2) (3) (4)
COMMON STOCK 09/18/2014   S   2,778 D $ 40.1568 (1) 2,923,015 I See Footnotes (2) (3) (4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The prices reported in Column 4 are weighted average prices. The shares sold on September 17, 2014 were sold at prices ranging from $40.00 to $40.80, inclusive. The shares sold on September 18, 2014 were sold at prices ranging from $40.00 to $40.77, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth above.
2. Shares of Common Stock are owned directly by Plio Limited ("Plio"), which holds less than 10% of the outstanding Common Stock of the issuer. Plio's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. Gregory Jankilevitsch , the sole shareholder of Plio, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. The shares owned by Plio do not include the 10,223,767 shares of the issuer's Common Stock held by Chione Limited, which has the same directors as Plio.
3. Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed, except, with respect to any person, to the extent of the pecuniary interest of such person in such securities.
4. Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
Remarks:
Exhibit Index Exhibit 24.1 - Power of Attorney, dated November 5, 2013, made by Marcin Czernik and Plio Limited in favor of Simon Prisk (previously filed) Exhibit 24.2 - Power of Attorney, dated November 5, 2013, made by Andreas Hadjimichael and Plio Limited in favor of Simon Prisk (previously filed) Exhibit 24.3 - Power of Attorney, dated November 5, 2013, made by Amalia Hadjimichael and Plio Limited in favor of Simon Prisk (previously filed) Exhibit 99.1 - Joint Filer Information (filed herewith) Exhibit 99.2 - Joint Filing Agreement (previously filed) All previously filed Exhibits were filed with the Form 3 of the reporting persons, Plio Limited and Gregory Jankilevitsch, filed on November 8, 2013.
Marcin Czernik, by /s/ Simon Prisk, as attorney-in fact by power of attorney 09/19/2014
** Signature of Reporting Person Date
/s/ Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney 09/19/2014
** Signature of Reporting Person Date
/s/ Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney 09/19/2014
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 99.1

 

Joint Filer Information

 

(Other Reporting Persons)

 

Name:

Andreas Hadjimichael 

   
Address:

Simou Menardou 8

Ria Court 8, Office 101

6015 Larnaca,  Cyprus

   

Designated Filer: 

 Marcin Czernik 
   

Issuer & Ticker Symbol:

Karyopharm Therapeutics Inc. [KPTI] 

Date of Earliest Transaction Required to Be Reported: 

09/17/2014

   
Relationship of Reporting Persons to Issuer:

10% Owner

   

If Amendment, Date Original Filed (Month/Day/Year):

 Not Applicable
   
Individual or Joint/Group Filing: Form filed by More than One Reporting Person
   
Signature and Date: Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact  by power of attorney 11/5/13

 

Name: Amalia Hadjimichael
   
Address:

Simou Menardou 8

Ria Court 8, Office 101

6015 Larnaca,  Cyprus

   
Designated Filer: Marcin Czernik
   
Issuer & Ticker Symbol: Karyopharm Therapeutics Inc. [KPTI]
   

Date of Earliest Transaction Required to Be Reported:

 

09/17/2014

Relationship of Reporting Persons to Issuer: 10% Owner
   
If Amendment, Date Original Filed  (Month/Day/Year): Not Applicable
   

Individual or Joint/Group Filing:

Form filed by More than One Reporting Person 

   
Signature and Date: Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in fact  by power of attorney 11/5/13